Kornimate/medical-research-clean huggingface dataset:
ketorolac in palatoplasty

Conditions: Cleft Lip and Palate

Summary: the purpose of this study is to see if the addition of iv ketorolac to usual care multi-modal pain therapy compared to usual care will improve oral intake post-operatively


Eligibility criteria:
inclusion criteria: -patient with cleft palate (complete and incomplete), with or without cleft lip, unilateral or bilateral exclusion criteria: * syndromic cleft palate patients * previous palatoplasty * major unrepaired cardiac malformation * history of gi complications (gi bleed, gastric ulceration) * history of renal disorder * history of coagulopathy (as contraindication to nsaid use) * feeding tube dependency * patients whose parents refuse to consent to randomization
quality of life during a twin pregnancy

Conditions: Twin Pregnancy

Summary: quality of life has recently appeared as a component of health. pregnancy has an impact on the quality of life of the parturient, whether through physical or psychological changes. it is common to think that quality of life is altered in the context of a twin pregnancy, but this has never been scientifically demonstrated. the hypothesis is to observe a decrease in the quality of life of pregnant women with twins at the end of pregnancy, in particular in case of a pregnancy-related pathology.


Eligibility criteria:
inclusion criteria: * woman over 18 * ongoing twin pregnancy (2 live fetuses) * pregnancy \<15 weeks (weeks of gestation) completed * patient with follow-up at the hôpital femme mère enfant * person having expressed her non-opposition exclusion criteria: * inability to understand the information given and the questionnaire * person deprived of liberty, under guardianship
pre-clinical diagnosis using integrated microbial and host response signatures to improve outcomes from ventilator-associated pneumonia in critically ill children

Conditions: Ventilator Associated Pneumonia ( VAP)

Summary: ventilator-associated pneumonia (vap), defined as pneumonia occurring 48 hours after initiation of invasive mechanical ventilation, is insidious in onset and severe in consequences. it is a critical issue affecting 10-20% of the 26,000 children admitted to the paediatric intensive care unit (picu) each year. infection typically leads to extended picu stay, prolonged invasive mechanical ventilation, and increased mortality. despite its clinical significance, vap remains poorly defined, as current diagnosis relies on non-specific criteria and the ability to obtain clinically meaningful cultures. vap, deviates from conventional pneumonia, potentially originating, from tissue damage, changes to immune processes, and migration of gastrointestinal bacteria into the lung; all associated with prolonged mechanical ventilation. these factors, in combination with the clinical instability of picu patients, mean that clinicians aggressively start antibiotic therapy despite a paucity of evidence to suggest the best regime. resultingly, suspected vap has been shown to account for nearly 40% of antibiotic exposure in the picu, which has significant implications on anti-microbial resistance (amr). to address these challenges, novel diagnostic therapies are needed to optimise the treatment of vap. these therapies should utilise our current understanding of the pathophysiology of vap development, specifically, the infiltration of the lung microbiome by gut and oral bacteria during prolonged mechanical ventilation. to achieve this, molecular testing should be promoted allowing for rapid identification of lung pathogens. there is also growing evidence, for the investigation of predictive biomarkers for vap available in both the blood and lungs, which when integrated into protocols may enhance diagnostic accuracy. these novel techniques may improve clinical outcomes for affected children while addressing the economic impact of prolonged hospital stays and mitigating amr risks in picus.


Eligibility criteria:
inclusion criteria: * picu admission * requires 48 hours of mechanical ventilation exclusion criteria: * imminent death or palliative care pathway planned * existing tracheostomy at time of admission * known immunocompromised patient * patient received a full course of systemic antimicrobials in the previous 6 weeks. * known or suspected tuberculosis (tb).

Keywords: respiratory tract infection paediatric intenstive care unit (picu) ventilator associated pneumonia immunology genomics
lithium dilution method in guiding fluid therapy in critically ill patients

Conditions: Critical Illness

Summary: hypothesis: fluid management guided by lidco doesn´t increase cumulative fluid balance and shorten organ dysfunction compared to fluid management based on cvp and clinical judgment.


Eligibility criteria:
inclusion criteria: * age * needs for fluid chalange * invasive ventilatory supportinvasive blood pressure monitoring * lidco monitoring * central venous catheter exclusion criteria: * dnr * need for crrt * head injury

Keywords: fluid lidco technology guided therapy fluid management guided by lidco technology
presence of pain shows greater effect than tendon structural alignment during landing dynamics

Conditions: Patellar Tendon; Athletes

Summary: the goal of this observational study is to investigate the relationship between temporal, kinetic, and kinematic jump variables and patellar tendons' structure in athletes. the main research questions are: does the structure of the patellar tendon relate to the temporal, kinetic, and kinematic variables of different jumps? to answer these questions, participants will undergo a utc (ultrasound tissue characterization) scan of the patellar tendon and perform two vertical jump: a countermovement jump and tuck jump test.


Eligibility criteria:
inclusion criteria: * aged between 18-30 years; * competing in the highest-level portuguese volleyball league with a minimum of 10 years of volleyball practice. exclusion criteria: * presence of injuries or discomfort that impeded maximal jumping tests; * history of surgery within the last 12 months; * illness during data collection

Keywords: jump performance patellar tendon tendon structure utc
e-health intervention (day-by-day) for the management of fear of progression in women with stage iii or iv gynecologic cancer: a pilot study

Conditions: Malignant Female Reproductive System Neoplasm; Stage III Cervical Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage III Vaginal Cancer AJCC v8; Stage III Vulvar Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IV Vaginal Cancer AJCC v8; Stage IV Vulvar Cancer AJCC v8

Summary: this clinical trial studies how well an electronic (e)-health intervention (day-by-day) woks in managing fears or worries about cancer growing, spreading, or getting worse (progression) in patients with stage iii or iv gynecologic cancer. fear and worries about cancer progression or recurrence (coming back) are common concerns. this may contribute to concerns related to illness, worries, and uncertainty about the future. day by day is adapted from a program called "conquer fear" which was shown to benefit patients with early-stage cancer. day-by-day intervention may help refocus patient thoughts and help patients learn skills to manage anxiety and fears.

primary objectives: i. will adapt the intervention into a hybrid format including two group and three web based self-study sessions. (phase 1) ii. to determine the feasibility and acceptability of a new hybrid e-health intervention to manage fear of progression (fop) in patients with stage iii or iv gynecologic (gyn) cancer. (phase 2) secondary objective: i. to explore the preliminary efficacy of day-by-day (dbd) on reducing fop (primary outcome) and improving secondary outcomes of distress, anxiety, depression, metacognitions, and mindfulness. (exploratory) outline: phase i (development): patients complete surveys and participate in focus groups. phase ii (dbd): patients receive dbd intervention consisting of group and web-based self-study sessions and check-in calls on study. patients also watch videos and receive handouts to reinforce the group sessions.

Eligibility criteria:
inclusion criteria: * women with stage iii or iv gyn cancer (ovarian, endometrial, cervical, vulvar/vaginal);at least 3 months from initial diagnosis * age: \>= 18 years * score \>= 34 on the fear of progression short-form, indicating dysfunctional levels * ability to read and understand english * patients in remission or with progressive disease are eligible exclusion criteria: * enrolled in hospice * severe depression as assessed by patient health questionnaire (phq-9) * non-english speaking * prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
effects of pregabalin on pain after total knee arthroplasty

Conditions: Primary Total Knee Arthroplasty

Summary: total knee arthroplasty can cause severe postoperative pain, and patients typically receive oral opioid analgesics for over 2 weeks. side effects of pain management may impair participation in physical therapy and diminish patient satisfaction. anecdotally, it seems that pregabalin is very helpful to patients after total knee arthroplasty. however, pregabalin can have side effects. it is not clear how much pregabalin to prescribe. low doses may not be effective, but use of high doses may increase the incidence and severity of side effects.the purpose of this study is to determine which dosage of pregabalin is the most effective at reducing pain after knee surgery.


Eligibility criteria:
inclusion criteria: * patients with osteoarthritis scheduled for primary tricompartmental total knee arthroplasty with a participating surgeon * age 18 to 80 years old * planned use of regional anesthesia * ability to follow study protocol * english speaking (primary outcome obtained via telephone call and secondary outcomes include questionnaires validated in english only) * patients planning on being discharged home or to a rehabilitation center that has agreed to participate exclusion criteria: * patients younger than 18 years old and older than 80 * patients intending to receive general anesthesia * allergy or intolerance to one of the study medications * patients with an asa of iv * patients with hepatic (liver) failure * patients with chronic renal (kidney) failure (defined as estimated creatinine clearance \< 30 ml/min, based on recommendation that total daily pregabalin dose be reduced to 150 mg with clcr \< 30 ml/min, clcr=\[(140-age (years)\] x weight (kg)x0.85 (for female patients)/\[72xserum creatinine (mg/dl)\]) * patients with difficult to manage diabetes mellitus, including insulin-dependence * chronic gabapentin/pregabalin use (regular use for longer than 3 months) * chronic opioid use (taking opioids for longer than 3 months) * patients with major prior ipsilateral open knee surgery. * chronic neurontin/lyrica use
predictive platform for people aged and requiring assistance

Conditions: Aging

Summary: the study aim is to assess the capacity of a technological solution for analyzing older person's functional and cognitive autonomy at home. results from this study will also be used to elaborate the design of a further larger national multicenter randomized control trial assessing the efficacy of the solution to detect early infra-clinical disability.

the object of the present project is to evaluate an instrument for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home. by assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss. the device consists of a set of sensors embedded in the house with minimal invasiveness. the solution transmits the collected data to a remote storage server. data will then be available for distance consultations by users (i.e., patients, careers or physicians). the study will conduct a wide range of evaluations of the device (technical, clinical, and economic), which will allow the optimization of the prototype. the evaluation of the solution will involve 25 frail or disable community-dwelling subjects living alone for 6 months. comprehensive assessments will be conducted to highlight the feasibility, integration in healthcare network, and clinical relevance of the technological device.

Eligibility criteria:
inclusion criteria: * patient aged 75 or more, living alone at home * frail of disable (adl superior or equal at 3) * able to walk by themselves exclusion criteria: * patient presenting a mini mental state lower at 16/30 and without a daily intervention from a caregiver * non agreement of study participation of patients or the reliable person when appropriate.

Keywords: elderly frailty tele-monitoring disability
performance, safety and efficiency comparison between 10,000 and 5,000 cuts per minute vitrectomy using a 25g cutter - a prospective randomized controlled study

Conditions: Vitreous Hemorrhage; Macula Hole; Epiretinal Membrane; Retinal Detachment

Summary: as technology advances, vitrectomy cutters are smaller and cut rates have become faster. in this prospective study, the vitrectomy efficiency and safety between 5,000 cuts per minute with 10,000 cuts per minute are compared

purpose: this study aims to compare the performance of the alcon 25+® ultravit® 5000 cpm vitrectomy probe versus the 25+® ultravit 10,000 cpm® beveled tip, dual drive vitrectomy probe. the safety profile and efficiency were compared. method: prospective, randomised study. consecutive patients from january 2019 to august 2019 requiring vitrectomy for retinal detachment, epiretinal membrane, vitreous haemorrhage, and macula hole were randomized into either the 10k or 5k vitrectomy group. both groups underwent vitrectomy using the proportional vacuum mode with the cut rate set at the fastest rate. patients with previous vitrectomy, other ocular diseases (glaucoma, corneal disease, or significant corneal opacities), or trauma were excluded from the study. the primary endpoint was vitrectomy time, while secondary endpoints included posterior vitreous detachment time, intraoperative complications, and number of instruments used. the preoperative, postoperative 1 month and 3 month best corrected visual acuity (bcva), and complications were recorded.

Eligibility criteria:
inclusion criteria: * consecutive patients over the age of 18 requiring vitrectomy for vitreous haemorrhage (vh), epiretinal membrane (erm), macular hole (mh), dislocated lens, rhegmatogenous retinal detachment and diabetic tractional retinal detachment were randomized into the study from january 2019 till august 2019 exclusion criteria: * patients with ocular comorbidities affecting surgical view including corneal opacities or scar, previous vitrectomy, history of trauma or requiring silicone oil were excluded from the study
the influence of different thyroid autoantibodies on thyroid function and pregnancy outcome after assisted reproductive technology

Conditions: Fertility Disorders; Thyroid Dysfunction

Summary: the influence of thyroid autoantibodies on thyroid function in pregnancy after fertility treatment is not well known. the objectives of the present study are: 1. to monitor the course of thyroid function during pregnancy and to compare between women with and without thyroid autoantibodies. 2. compare pregnancy outcome between women with and without thyroid antibodies

thyroid autoantibodies and / or abnormal thyroid function are associated with fertility problems. a possible explanation for this is, an influence of thyroid autoantibodies on the functioning of the thyroid gland. it is therefore recommended to check thyroid gland function and for the presence of autoantibodies before pregnancy. in general, 2 types of thyroid autoantibodies are known: anti-thyreoperoxidase autoantibodies and anti-thyroglobulin autoantibodies. in case of abnormal thyroid function, treatment is sometimes necessary in regards to fertility. the risk of abnormal thyroid function is increased in women with thyroid autoantibodies during pregnancy. therefore, thyroid function is regularly monitored during pregnancy in women with thyroid antibodies. the influence of thyroid autoantibodies on thyroid function in pregnancy after fertility treatment is not well known. the objectives of the present study are: 1. to monitor the course of thyroid function during pregnancy and to compare between women with and without thyroid autoantibodies. 2. compare pregnancy outcome between women with and without thyroid antibodies

Eligibility criteria:
inclusion criteria: * first cycle of assisted reproductive technology with follow up of thyroid function at the universitair ziekenhuis brussel * age \>= 18 and \<= 36 years * body mass index between 18 and 35 exclusion criteria: * patients with clinical thyroid dysfunction * patients being treated with levothyroxine or antithyroid drugs * patients being treated with glucocorticosteroids * patients undergoing in vitro maturation or preimplantation genetic testing. * poor responders during ivf/icsi stimulation, using the bologna criteria
evaluation of chronic liver disease condition and transplant prognosis assisted by eye biological parameters

Conditions: Diagnostic Techniques, Ophthalmological; Liver Transplantation; Liver Cirrhoses

Summary: this study investigates the correlation between ocular biological characteristics and overall conditions before and after liver transplantation by collecting ocular biological characteristics. explore whether it is possible to construct a clinical prediction model for liver transplantation by incorporating ocular biometric features, in order to optimize disease management before and after liver transplantation.

this study is a bidirectional cohort study, which retrospectively analysed data from a prospective database to construct a model, and prospectively collected patient information from preoperative to postoperative for model improvement and validation.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years old; 2. late stage liver disease patients waiting for liver transplantation treatment, as well as patients with varying degrees of cirrhosis; 3. can collect complete basic demographic information, liver function blood test indicators, liver pathology and imaging examination results; 4. can cooperate with eye oct, octa and other examinations, and obtain qualified examination parameters; 5. voluntarily follow the clinical trial protocol and sign the informed consent form. exclusion criteria: 1. history of other organ transplant surgeries; 2. history of intraocular laser treatment, medication injection, and surgery; 3. history of high myopia, glaucoma, and retinal choroidal related eye diseases; 4. history of major systemic diseases other than liver disease; 5. individuals whose overall body and eye conditions cannot cooperate with eye examinations.

Keywords: diagnostic techniques, ophthalmological liver transplantation liver cirrhoses
biomarkers in a candian memory clinic

Conditions: Alzheimer&#39;s Disease (AD)

Summary: this is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. this study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (dmt)) to triage patients towards biological staging of disease with biomarker testing.


Eligibility criteria:
inclusion criteria: 1. individual with mci (if not yet diagnosed, individuals with amnestic changes in memory as shown on moca) 2. moca score must be 18 to 28 inclusive 3. age 55 to 80 years inclusive 4. has a study partner that is willing to participate as a source of information and has approximately weekly contact with the subject (contact can be in-person, via telephone or electronic communication). the study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the subject's daily function. 5. group a - must have a clinical memory assessment appointment scheduled at parkwood institute within 18 months of baseline 6. group b - must have had a clinical memory assessment appointment at parkwood institute within 18 months of baseline exclusion criteria: * 1) participants who fulfill diagnostic criteria for mci or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than ad (eg, mci/dementia due to frontotemporal lobar degeneration, diffuse lewy body disease, parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, etc). 2) presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest huntington's disease, multiple sclerosis, parkinson's disease, down's syndrome, active alcohol/drug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder. 3) current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures 4) history of epilepsy, fits, or unexplained blackouts other than vasovagal syncope within 10 years before screening. 5) malignant neoplasms within 3 years (except for basal cell or squamous cell carcinoma in situ of the skin) 6) women of child bearing potential and breastfeeding mothers 7) individuals who require sedation to complete pet scan. 8) individuals who are unable to complete assessments in the english language. 9) individuals who cannot provide consent

Keywords: mild cognitive impairment dementia biomarkers
larotaxel compared to continuous administration of 5-fu in advanced pancreatic cancer patients previously treated with a gemcitabine-containing regimen

Conditions: Pancreatic Neoplasms

Summary: the purpose of this study is to compare the efficacy and the safety larotaxel administered as single agent every 3 weeks to continuous administration of 5-fu every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.


Eligibility criteria:
inclusion criteria: * advanced (non operable in a curative intent, locally recurrent or metastatic disease) cytologically or histologically proven epithelial cancer (adenocarcinoma) of the exocrine pancreas. * patient must be previously treated with a systemic gemcitabine based regimen * adequate bone marrow, kidney and liver functions exclusion criteria: * ecog performance status (ps) of 2-3-4. * prior locoregional radiotherapy for pancreatic cancer. * symptomatic brain metastases or leptomeningeal disease. * any serious intercurrent infections, uncontrolled cardiac or gastro-intestinal diseases. * other concurrent malignancy * other protocol-defined exclusion/inclusion criteria may apply

Keywords: advanced pancreatic cancer